FDA Clearance Tracker · K262419
MICRUSFRAME (MFR100202); MICRUSFRAME (MFR100253); MICRUSFRAME (MFR100305); MICRUSFRAME (MFR100356); MICRUSFRAME (MFR100407); MICRUSFRAME (MFR100412); MICRUSFRAME (MFR100509); MICRUSFRAME (MFR100517); MICRUSFRAME (MFR100611); MICRUSFRAME (MFR100626); MICRUSFRAME (MFR100713); MICRUSFRAME (MFR100730); MICRUSFRAME (MFR100816); MICRUSFRAME (MFR100829); MICRUSFRAME (MFR140225); MICRUSFRAME (MFR140303); MICRUSFRAME (MFR140304); MICRUSFRAME (MFR140306); MICRUSFRAME (MFR140406); MICRUSFRAME (MF
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 14, 2026
Substantially Equivalent
Time to decision
30 days
Received Jul 15, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K262419
- Device name
- MICRUSFRAME (MFR100202); MICRUSFRAME (MFR100253); MICRUSFRAME (MFR100305); MICRUSFRAME (MFR100356); MICRUSFRAME (MFR100407); MICRUSFRAME (MFR100412); MICRUSFRAME (MFR100509); MICRUSFRAME (MFR100517); MICRUSFRAME (MFR100611); MICRUSFRAME (MFR100626); MICRUSFRAME (MFR100713); MICRUSFRAME (MFR100730); MICRUSFRAME (MFR100816); MICRUSFRAME (MFR100829); MICRUSFRAME (MFR140225); MICRUSFRAME (MFR140303); MICRUSFRAME (MFR140304); MICRUSFRAME (MFR140306); MICRUSFRAME (MFR140406); MICRUSFRAME (MF
- Applicant
- Cerenovus, Inc.
- Applicant location
- Irvine, CA
- Received
- Jul 15, 2026
- Decided
- Aug 14, 2026
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Device, Neurovascular Embolization (HCG)
- Device class
- Class II
- Regulation
- 21 CFR 882.5950
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code HCG. The earliest in FDA's data is K871047, decided May 22, 1987.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K262419
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Cerenovus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262398 · Decided Aug 13, 2026 · 30 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
- TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural SetPMA supplement
P990040-S034 · Decided Dec 16, 2025 · 316 days after receipt · Panel Track
Device type: Neurovascular Liquid Embolic Agent (SGU) · Neurology & Neurosurgery
K251828 · Decided Aug 22, 2025 · 70 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.